A Randomized Placebo-Controlled Trial of Nicotinamide Riboside in Older Adults with Mild Cognitive Impairment

Objective

To determine the safety of oral NR supplementation in older adults with mild cognitive impariment (MCI), and investigate its effects on cognition, brain volume and functioning, and physical function.

Study Design

Randomized, double-blind, placebo-controlled, phase II, pilot study in 20 primarily Hispanic older adults with MCI

Dose

1000 mg

Duration

10 weeks

Key Outcomes

  • Cognitive function measures remained stable in both NR and placebo groups throughout the study.

  • Global methylation analyses trended towards a modest NR-associated increase in DNA methylation.

Clinical, Neurological HealthANAD StaffNeurological Health, Mild Cognitive Impairment